FREMONT, Calif., Nov. 10 /PRNewswire-FirstCall/ -- WaferGen Biosystems,
Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art
gene expression, genotyping, cell biology and stem cell research systems,
today highlighted the company's recent developments and announced financial
results for the quarter and nine months ended September 30, 2008.
Recent Corporate Developments:
-- Announced that the National Institutes of Health (NIH) has awarded a
team of researchers at the University of Pittsburgh an approximately $3
million grant to conduct novel gene expression research in the area of
lung disease involving WaferGen's SmartChip(TM) Real-Time PCR System.
NIH-funded research will include the development and application of the
PulmoSmartChip, a custom designed SmartChip molecular phenotyping assay
for chronic obstructive pulmonary disease (COPD) and idiopathic
pulmonary fibrosis (IPF).
-- Expanded worldwide sales network for WaferGen's SmartSlide(TM) Micro-
Incubation System by signing regionally exclusive agreements with
leading distributors of innovative products and services to cell
biologists and stem cell researchers in Switzerland, Taiwan, the Nordic
region and Italy. Most recently, the company also signed a
distribution agreement to support sales in Japan.
"Consistent with our goals for this year, we are pleased that the NIH
and the University of Pittsburgh are supporting key research initiatives
using our SmartChip Real-Time PCR System. We believe the results from this
research will facilitate the ongoing advancement of the SmartChip system as
the platform of choice for biomarker discovery and validation," stated
Alnoor Shivji, WaferGen's chairman and chief executive officer. "In
addition, we continued to expand our reach and customer base for our
SmartSlide Micro- Incubation System family of product
|SOURCE WaferGen Biosystems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved